Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958234 | 0.81 | CYP2A6 (0.39) | CYP2A6MAOAMAOBERN1PGK1 | |
| SCHEMBL14017919 | 0.81 | CYP2A6 (0.39) | CYP2A6MAOAMAOBERN1PGK1 | |
| SCHEMBL501537 | 0.79 | CYP2A6 (0.38) | CYP2A6MAOAMAOBERN1PGK1 | |
| SCHEMBL26049058 | 0.79 | ERN1 (0.39) | CYP2A6MAOAMAOBERN1PGK1 | |
| SCHEMBL28027680 | 0.78 | FFAR4 (0.39) | CYP2A6MAOAMAOBERN1PGK1 | |
| SCHEMBL280640 | 0.77 | CYP2A6 (0.52) | CYP2A6ERN1SRC | |
| SCHEMBL3129625 | 0.77 | CYP2A6 (0.52) | CYP2A6ERN1SRC | |
| SCHEMBL15591000 | 0.77 | ALDH1A1 (0.40) | MAOAPGK1PGK2 | |
| SCHEMBL13985153 | 0.77 | PGK1 (0.42) | PGK1PGK2 | |
| SCHEMBL17749096 | 0.76 | CYP2A6 (0.35) | CYP2A6MAOAMAOBERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX, LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-7763642-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LTD. (GB) | 2010-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | CYP19A1, CYP17A1, CYP21A2 | CYP2A6 109/4885MAOA 142/4885MAOB 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.